[Business Wire] - Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that additional data from AbbVie's M13-393 study, referred to as PEARL-I, will be presented in an oral presentation at 5:15 p.m.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment